B. Riley Cuts Cumberland Pharmaceuticals (CPIX) Price Target to $8.75
Cumberland Pharmaceuticals (NASDAQ:CPIX) had its price objective lowered by B. Riley from $9.25 to $8.75 in a research note released on Friday morning. The firm currently has a buy rating on the specialty pharmaceutical company’s stock.
Separately, ValuEngine raised shares of Cumberland Pharmaceuticals from a sell rating to a hold rating in a research note on Wednesday, May 2nd.
Shares of CPIX opened at $5.50 on Friday. The company has a current ratio of 4.10, a quick ratio of 3.70 and a debt-to-equity ratio of 0.20. The company has a market cap of $92.69 million, a P/E ratio of -78.57 and a beta of 0.65. Cumberland Pharmaceuticals has a 1 year low of $5.50 and a 1 year high of $7.96.
Several institutional investors and hedge funds have recently made changes to their positions in CPIX. Ariel Investments LLC lifted its stake in shares of Cumberland Pharmaceuticals by 28.7% during the second quarter. Ariel Investments LLC now owns 1,305,052 shares of the specialty pharmaceutical company’s stock valued at $8,000,000 after buying an additional 291,126 shares during the period. Renaissance Technologies LLC lifted its stake in shares of Cumberland Pharmaceuticals by 6.7% during the second quarter. Renaissance Technologies LLC now owns 377,209 shares of the specialty pharmaceutical company’s stock valued at $2,312,000 after buying an additional 23,709 shares during the period. Finally, Prudential Financial Inc. purchased a new position in shares of Cumberland Pharmaceuticals during the first quarter valued at approximately $138,000. 34.52% of the stock is currently owned by institutional investors and hedge funds.
About Cumberland Pharmaceuticals
Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, together with its subsidiaries, focuses on acquiring, developing, and commercializing branded prescription products for hospital acute care, gastroenterology, and oncology markets in the United States and internationally. Its marketed products include Acetadote (acetylcysteine) injection for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) injection for the treatment of pain and fever; Kristalose (lactulose) for the treatment of chronic and acute constipation; Vaprisol (conivaptan) injection for treating hyponatremia; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Ethyol (amifostine) for injection to treat oncology patients; and Totect Injection for the treatment of toxic effects.
Further Reading: Fundamental Analysis and Choosing Stocks
Receive News & Ratings for Cumberland Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumberland Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.